|
Total patients
|
Non-antiplatelet HAS-BLED score
|
p
|
---|
|
0–2
|
3 or more
|
---|
All CAD, n (%)
|
408
|
353
|
55
| |
No antiplatelet
|
222 (54.4%)
|
196 (55.5%)
|
26 (47.3%)
|
0.253
|
Single antiplatelet
|
153 (37.5%)
|
128 (36.3%)
|
25 (45.5%)
|
0.190
|
Dual antiplatelets
|
33 (8.1%)
|
29 (8.2%)
|
4 (7.3%)
|
1.000
|
DES < 1 year, n (%)
|
27
|
23
|
4
| |
No antiplatelet
|
3 (11.1%)
|
3 (13.0%)
|
0 (0.0%)
|
1.000
|
Single antiplatelet
|
7 (25.9%)
|
6 (26.1%)
|
1 (25.0%)
|
1.000
|
Dual antiplatelets
|
17 (63.0%)
|
14 (60.9%)
|
3 (75.0%)
|
1.000
|
DES > 1 year or BMS for any duration, n (%)
|
125
|
108
|
17
| |
No antiplatelet
|
41 (32.8%)
|
35 (32.4%)
|
6 (35.3%)
|
0.814
|
Single antiplatelet
|
73 (58.4%)
|
63 (58.3%)
|
10 (58.8%)
|
0.970
|
Dual antiplatelets
|
11 (8.8%)
|
10 (9.3%)
|
1 (5.9%)
|
1.000
|
History of ACS within 1 year, n (%)
|
42
|
33
|
9
| |
No antiplatelet
|
21 (50.0%)
|
17 (51.5%)
|
4 (44.4%)
|
1.000
|
Single antiplatelet
|
12 (28.6%)
|
9 (27.3%)
|
3 (33.3%)
|
0.699
|
Dual antiplatelets
|
9 (21.4%)
|
7 (21.2%)
|
2 (22.2%)
|
1.000
|
CAD without prior ACS or PCI, n (%)
|
386
|
332
|
54
| |
No antiplatelet
| |
189 (56.9%)
|
26 (48.1%)
|
0.102
|
Single antiplatelet
| |
115 (34.6%)
|
25 (46.3%)
|
0.053
|
Dual antiplatelets
| |
28 (8.4%)
|
3 (5.6%)
|
1.000
|
- A p-value < 0.05 indicates statistical significance
- OAC, oral anticoagulant; HAS-BLED, Hypertension, Abnormal liver/renal function, Stroke history, Bleeding history or predisposition, Labile INR, Elderly, Drug/alcohol usage; CAD, coronary artery disease; DES, drug-eluting stent; BMS, bare-metal stent; ACS, acute coronary syndrome; PCI, percutaneous coronary intervention